TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer.
BRAF
Colorectal neoplasms
Fluorouracil
KRAS
Prognosis
Thymidylate synthase
Untranslated regions
Journal
World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470
Informations de publication
Date de publication:
15 Jul 2019
15 Jul 2019
Historique:
received:
14
03
2019
revised:
30
04
2019
accepted:
12
06
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
2
8
2019
Statut:
ppublish
Résumé
Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment decisions in these patients. Thymidylate synthase ( To investigate the association of A retrospective study studied formalin-fixed paraffin-embedded tissues (FFPEs) of consecutive patients treated with adjuvant chemotherapy during January/2005-January/2007. FFPEs were analysed with PCR for the detection of One hundred and thirty patients with early stage CRC (stage I-II: 55 patients; stage III 75 patients; colon: 70 patients; rectal: 60 patients) were treated with surgery and chemotherapy. The 5-year disease free survival and overall survival rate was 61.6% and 73.9% respectively. 5'UTR polymorphisms of intermediate Prospective validating studies are required to confirm whether 2RG/3RG, 2RG/LOH, 3RC/LOH, absence of ins/LOH and wild type
Sections du résumé
BACKGROUND
BACKGROUND
Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment decisions in these patients. Thymidylate synthase (
AIM
OBJECTIVE
To investigate the association of
METHODS
METHODS
A retrospective study studied formalin-fixed paraffin-embedded tissues (FFPEs) of consecutive patients treated with adjuvant chemotherapy during January/2005-January/2007. FFPEs were analysed with PCR for the detection of
RESULTS
RESULTS
One hundred and thirty patients with early stage CRC (stage I-II: 55 patients; stage III 75 patients; colon: 70 patients; rectal: 60 patients) were treated with surgery and chemotherapy. The 5-year disease free survival and overall survival rate was 61.6% and 73.9% respectively. 5'UTR polymorphisms of intermediate
CONCLUSION
CONCLUSIONS
Prospective validating studies are required to confirm whether 2RG/3RG, 2RG/LOH, 3RC/LOH, absence of ins/LOH and wild type
Identifiants
pubmed: 31367274
doi: 10.4251/wjgo.v11.i7.551
pmc: PMC6657223
doi:
Types de publication
Journal Article
Langues
eng
Pagination
551-566Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Références
Genomics. 1999 Jun 15;58(3):310-2
pubmed: 10373329
Clin Cancer Res. 2000 Dec;6(12):4797-802
pubmed: 11156237
J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74
pubmed: 11459867
Clin Cancer Res. 2001 Dec;7(12):4096-101
pubmed: 11751507
Oncol Rep. 2002 Mar-Apr;9(2):231-4
pubmed: 11836585
J Clin Oncol. 2002 Apr 1;20(7):1721-8
pubmed: 11919227
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Cancer Res. 2003 Jun 1;63(11):2898-904
pubmed: 12782596
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3700-4
pubmed: 14506161
J Clin Oncol. 2004 Feb 1;22(3):529-36
pubmed: 14752076
Clin Cancer Res. 2004 Jan 15;10(2):433-9
pubmed: 14760062
Pharmacogenetics. 2004 May;14(5):319-27
pubmed: 15115918
Clin Cancer Res. 2004 Sep 1;10(17):5880-8
pubmed: 15355920
N Engl J Med. 2005 Jun 30;352(26):2696-704
pubmed: 15987918
Pharmacogenet Genomics. 2005 Oct;15(10):723-30
pubmed: 16141798
Invest New Drugs. 2005 Dec;23(6):533-7
pubmed: 16267625
J Clin Oncol. 2006 Apr 1;24(10):1603-11
pubmed: 16575011
Ann Oncol. 2006 Dec;17(12):1810-7
pubmed: 16971666
Oncol Rep. 2006 Nov;16(5):1111-5
pubmed: 17016601
Oncology. 2006;70(5):366-77
pubmed: 17179731
Eur J Cancer. 2007 Mar;43(5):955-62
pubmed: 17317154
Oncol Rep. 2007 Jul;18(1):287-91
pubmed: 17549381
Clin Colorectal Cancer. 2007 Nov;6(10):720-7
pubmed: 18039426
Lancet. 2007 Dec 15;370(9604):2020-9
pubmed: 18083404
Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31
pubmed: 18568040
Cancer Lett. 2008 Dec 18;272(2):221-5
pubmed: 18722050
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8977-81
pubmed: 1924359
Gastrointest Cancer Res. 2007;1(4 Suppl 2):S47-9
pubmed: 19360148
Mol Cancer Ther. 2009 May;8(5):1037-44
pubmed: 19383847
J Clin Oncol. 2009 Jul 1;27(19):3109-16
pubmed: 19451431
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12938-43
pubmed: 19622726
BMC Cancer. 2009 Sep 24;9:339
pubmed: 19775480
J Surg Oncol. 2010 Jan 1;101(1):22-7
pubmed: 19798689
Clin Cancer Res. 2009 Dec 1;15(23):7322-9
pubmed: 19934290
J Clin Oncol. 2010 Jan 20;28(3):466-74
pubmed: 20008640
Lancet. 2010 Mar 20;375(9719):1030-47
pubmed: 20304247
Lancet Oncol. 2010 Aug;11(8):753-62
pubmed: 20619739
Anticancer Res. 2010 Jun;30(6):1969-75
pubmed: 20651341
J Clin Oncol. 2011 Apr 1;29(10):1261-70
pubmed: 21383284
Pharmacol Res. 2011 Sep;64(3):242-8
pubmed: 21536130
Cell Oncol (Dordr). 2011 Aug;34(4):327-35
pubmed: 21630057
Clin Cancer Res. 2012 Feb 1;18(3):890-900
pubmed: 22147942
J Clin Oncol. 2012 Jul 20;30(21):2624-34
pubmed: 22665536
Oncol Lett. 2012 May;3(5):983-989
pubmed: 22783377
Genet Test Mol Biomarkers. 2013 Nov;17(11):799-806
pubmed: 23968134
J Clin Oncol. 2014 Apr 1;32(10):1031-9
pubmed: 24590654
Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):481-90
pubmed: 24685603
Br J Cancer. 2014 May 27;110(11):2728-37
pubmed: 24800948
Anticancer Res. 2014 Sep;34(9):4949-62
pubmed: 25202077
Cancer Biomark. 2015;15(1):65-78
pubmed: 25524944
World J Gastroenterol. 2015 Jan 28;21(4):1275-83
pubmed: 25632202
Mol Oncol. 2015 Aug;9(7):1341-7
pubmed: 25864038
Br J Cancer. 2015 Jun 9;112(12):1966-75
pubmed: 25973534
JAMA Oncol. 2016 May 1;2(5):643-653
pubmed: 26768652
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Clin Gastroenterol Hepatol. 2016 May;14(5):651-8
pubmed: 26872400
PLoS One. 2016 May 03;11(5):e0154795
pubmed: 27138801
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Ann Oncol. 2017 May 1;28(5):958-968
pubmed: 28453690
World J Gastroenterol. 2017 Aug 28;23(32):5913-5924
pubmed: 28932083
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cell Struct Funct. 1995 Jun;20(3):191-7
pubmed: 7586009
Ann Intern Med. 1995 Mar 1;122(5):321-6
pubmed: 7847642
Mol Cell Biol. 1994 Jan;14(1):207-13
pubmed: 8264588